"Humans and other mammals"@en . " "@en . . . . "Bestatin"@en . "58970-76-6"@en . . . . . . . . . . . . . . . . . "Ubenimex"@en . . . . . "Hamao Umezawa, Takaaki Aoyagi, Tomio Takeuchi, Masa Hamada, Yoshiro Okami, \"Biologically active substance, bestatin, and production thereof.\" U.S. Patent US4052449, issued October 04, 1977."@en . . . . . "Bestatin is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia."@en . . "An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia."@en . . . "experimental"@en . . . . "# Scornik OA, Botbol V: Bestatin as an experimental tool in mammals. Curr Drug Metab. 2001 Mar;2(1):67-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11465152 # Yoneda J, Saiki I, Fujii H, Abe F, Kojima Y, Azuma I: Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). Clin Exp Metastasis. 1992 Jan;10(1):49-59. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1733647 # Bauvois B, Dauzonne D: Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006 Jan;26(1):88-130. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16216010 # Wickstrom M, Larsson R, Nygren P, Gullbo J: Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011 Mar;102(3):501-8. doi: 10.1111/j.1349-7006.2010.01826.x. Epub 2011 Jan 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21205077"@en . .